Successful gene therapy for brain diseases is de pendent on obtaining stable expression of a func tional transgene product in an appropriate popula tion of cells in the CNS. The development of vec tors that facilitate the entry and expression of therapeutic DNA in specific types of brain cells and the selection of methods for delivery of the vectors to the target cell popUlations are major obstacles that must be overcome to achieve this goal.
Considerable progress has been made in the use of viruses as vectors for the transfer of foreign DNA into many different cells, including those of the brain (Mulligan, 1993) . Adenoviruses show particu-for l3-galactosidase 5 days after virus injection indicated that transgene expression was confined primarily to the cells lining the ventricle. The concentrations of IL-lra were fivefold to 50-fold higher in the Ad.RSVIL-lra injected animals, achieving levels of 9.1 ± 3.3 ng/g in brain and 23.7 ± 22.5 ng/ml in CSF. In these animals, cerebral infarct volume resulting from 24 h of permanent middle cerebral artery occlusion was reduced 64%. These studies demonstrate that adenoviral vectors can be used to deliver genes that attenuate brain injury. Key Words: Gene therapy-Adenovirus vectors-Cerebral isch emia-Stroke-Interleukin-l. lar promise as versatile delivery agents because they are capable of infecting a variety of postmi totic, terminally differentiated cells. Several recent reports document the expression of the gene for Escherichia coli f3-galactosidase (lacZ) for up to 8 weeks after the injection into brain of replication deficient recombinant adenoviruses carrying the lacZ gene (Akli et aI., 1993; Bajocchi et aI., 1993; Davidson et aI., 1993) . Direct intraparenchymal in jection of the recombinant adenovirus resulted in lacZ expression in neurons and glia (Akli et aI., 1993; Davidson et aI., 1993) , whereas injection of virus into the cerebral ventricles favored expression in the ependymal cells (Akli et aI., 1993; Bajocchi et aI., 1993) .
Although these studies demonstrate the feasibil ity of delivering and achieving expression of a bac terial enzyme that serves as a marker of infected cells, they do not provide evidence that adenovi: ruses can be used to deliver genes that can modify the course of neurologic disease. In our study, we used an adenovirus containing the gene for human interleukin-l rece p tor antagonist p rotein (lL-l ra) to p roduce high levels of IL-lra in CSF and brain. Because direct injection of this p rotein into the ce rebral ventricles has been shown p reviously to at tenuate ischemic injury in brain (Relton and Roth well, 1992) , we studied the effect of adenoviral mediated overex p ression of IL-lra on brain injury in a rat model of stroke.
METHODS
The construction of replication-deficient human adeno virus serotype 5-derived adenoviral vectors is described elsewhere . For our experi ment, two different recombinant viruses were con structed. One contained the human IL-lra eDNA (Roes sler et aI., 1995) , and the other contained the lacZ gene. Both used the Rous sarcoma virus (RSV) promoter to drive gene transcription. These vectors are designated Ad.RSVlL-lra and Ad.RSVlacZ, respectively. The Ad.RSVlacZ served both as a control virus carrying a gene not expected to alter cerebral injury and as a re porter virus to indicate the distribution of transduced cells after virus administration.
The eDNA for human IL-lra was a gift of Immunex and was used in the construction of Ad.RSVIL-lra. The eDNA was cloned into the adenoviral shuttle plasmid pAdRSV4. This shuttle plasmid contains the RSV pro moter, a small multiple cloning site, and a polyadenylic acid (polyA) signal. The cassette is flanked by Ad5 se quences (0--1 map unit on the 5' end; 9-16 map units on the 3' end) necessary for homologous recombination. Both Escherichia coli lacZ and IL-lra sequences were cloned into pAdRSR4, as previously reported (Davidson et aI., 1993; Roessler et aI., 1995) . Recombinant plaques were scored for appropriate sequences by Southern blot ting, expanded, and purified before large-scale amplifica tion. Purification was done by CsCI banding and desalting over Sephadex G-50.
Adenovirus vectors were administered by direct injec tion into the left lateral cerebral ventricle. Sprague-Daw ley rats weighing 220--250 g were anesthetized with 2% isoflurane in 70% NzO/30% 0z, and their heads were se cured in a stereotactic frame. A 26-gauge needle was in serted into the lateral ventricle, as described previously (Dickinson and Betz, 1992) . Ten microliters of adenoviral suspension containing 1 x 1011 particles/ml (i.e., I x 109 particles total) was injected stereotactically into the lat eral ventricle at a rate of � 1 ILl/min. The needle was then withdrawn over the course of 5 min, and the wounds were closed with suture.
Some of the rats that received Ad.RSVlacZ were killed, and the brains were perfusion fixed with 2% paraformaldehyde in 0.1 mM PIPES, pH 6.9. The brains were removed and sliced into 2-mm thick coronal slices. The slices were reacted with 5-bromo-4-chloro-3-indolyl j3-D-galactoside (X-gal) to identify lacZ-expressing cells, as described previously (Davidson et aI., 1993) .
Five days after administration of virus, the rats were reanesthetized with 2% isoflurane in 70% NzO/30% 02' and focal cerebral ischemia was produced by occlusion of the left middle cerebral artery (MCAO) using a 3-0 silk suture advanced through the internal carotid artery , as described previously (Longa et aI., 1989; Yang et aI., J Cereb Blood Flow Metab, Vol. 15. No.4, 1995 ). The production of ischemia was confirmed by sur face blood flow measurement using a laser Doppler flow meter (LDF), as described elsewhere (Yang and Betz, 1994) . Stable baseline LDF readings were recorded for 20 min before occlusion and after 10 and 60 min of ischemia. The ischemic CBF values were calculated as percentage of the preis chemic LDF values (Yang et aI., 1994) . After I h of monitoring, the anesthesia was discontinued, and the animals were allowed to recover. An additional group of six "untreated" rats were subjected to MCAO without any previous adenovirus inoculation.
Approximately 23 h after MCAO, rats were reanesthe tized, and a polyethylene cannula was placed in a femoral artery to monitor blood pressure and to obtain a blood sample. A small incision was made over the foramen mag num, and a 26-gauge needle was used to pierce the dura and obtain �50 ILl of CSF. The rats were then decapi tated, and the brains were removed immediately . Six co ronal slices 2, 4, 6, 8, 10, and 12 mm distal from the frontal pole were dissected using a brain slicer. These brain slices were stained with 2% (wt/vol) 2,3,5-triphen yltetrazolium chloride (TTC) in Dulbecco's phosphate buffer (pH 7.4) at 37°C for 20 min (Imaizumi et aI., 1990) . TTC stains mitochondrial dehydrogenase and accurately delineates the infarct area as compared with traditional staining techniques (Bederson et aI., 1986; Lundy et aI., 1986) . The area of infarction in each slice was analyzed by a computerized image-analy sis sy stem. The volume of infarction was calculated by summing the products of the distance between sections and the infarct areas (Swanson et al., 1990) .
A group of virus-injected animals that were not sub jected to MCAO were used to measure brain and CSF concentrations of human IL-lra. Samples of brain from the left cerebral cortex were weighed and homogenized in 50 mM potassium phosphate buffer, pH 6.0. After cen trifugation at 30,000 g for 30 min, the supernates were collected and used for the assay. CSF samples were as sayed without further processing. Samples were diluted between I to 50 and 1 to 100 in assay buffer for use in a commercially available human IL-lra enzyme-linked im munosorbent assay (ELISA) assay kit (Quantikine, R&D Sy stems). Authentic human IL-lra was used for the stan dard curve.
Values are presented as means ± SD. Significant dif ferences between groups were identified using a two tailed Student's t test for unpaired samples. Figure 1 shows the distribution of brain regions infected with Ad.RSVlaeZ after intraventricular in jection of the virus. Prominent laeZ ex p ression is observed in the cells lining the ventricles, confirm ing p revious re p orts (Akli et aI., 1993; Bajocchi et aI., 1993) . Staining was also seen along the needle track and occasionally dee p within the cerebral cor tex distant from the site of injection. However, most of the cerebral cortex was free of X-gal stain ing. Microsco p ic examination confirmed ·the ab sence of X-gal-stained cells in the cerebral cortex (not shown).
RESULTS AND DISCUSSION
Intraventricular injection of Ad .RSV IL-J ra re- suited in a marked increase in the concentration of IL-lra in CSF and brain 5 days later (Table 1) . Sur p risingly, the concentration in cerebral cortex (9 ng/g wet weight) was similar to the concentration of CSF (23 ng/mi), des p ite the fact that there was only minimal evidence of virus infection in the cerebral cortex. Although the concentration of substances within the extracellular fluid of the brain is gener ally believed to be in equilibrium with the CSF con centrations (Betz et aI., 1994) , the extracellular fluid com p oses only -20% of the brain (Fenstermacher, 1984) . Thus the equivalent levels of IL-Ira in brain and CSF suggest that the p rotein had either bound to or entered the brain cells from the extracellular fluid or some of the cells in the sam p led tissue were infected with virus and p roducing IL-lra. The latter p ossibility is likely because brain tissue was sam p led on the same side as the virus injection and, as shown in Fig. I, some infected cells are observed along the needle track.
There were no differences in body tem p erature (37.5 ± 0.1 versus 37. 3 ± 0.3), blood p ressure, ar .. terial p H, Pc02, Po2, and hematocrit 24 h after MCAO in rats that had received Ad.RSVIL-lra com p ared to those that received Ad.RSVlacZ. The IL-I ra recombinant virus had no effect on weight gain during the 5 days after virus injection or on the mild weight loss that occurs during the first 24 h after MCAO (data not shown). Relative CBF was reduced similarly in both grou p s after MCAO (20 ± 6 versus 20 ± 13% of control at 10 min after MCAO and 17 ± 2 versus 16 ± 9% of control at 60 min after MCAO in animals receiving Ad.RSVIL-lra or Ad.RSVlacZ, res p ectively). The CSF concentra tions of IL-1ra remained elevated 24 h after MCAO in animals that received Ad.RSVIL-lra (13.0 ± 3.7 versus 0.8 ± 0.8 ng/ml).
Finally, the extent of ischemic injury was mea sured using TTC as a stain to identify infarcted brain tissue. As shown in Fig. 2 , the infarct volume in Ad.RSVIL-lra-treated rats (46 ± 53 mm3) was significantly less than that of Ad.RSVlacZ-treated rats (126 ± 36 mm3, p < 0.05). This 64% reduction in stroke volume is even greater than the 50% re duction re p orted by Relton and Rothwell (1992) af ter direct injections of recombinant human IL-1ra. It is uncertain whether the greater p rotection ob served in our study is due to a higher or more p er sistent IL-1ra level in brain and CSF (or both) with use of the adenoviral vector or the larger stroke size produced by our model. One concern with the use of adenovirus to induce the ex p ression of p roteins that reduce the inflam matory res p onse is that the viral infection itself may cause significant inflammation and p erha p s increase brain injury. Although the extent of the inflamma tory res p onse caused by the AdRSV vector was not determined in our study, it does not a pp ear that the ischemic injury was accentuated by the adenovirus, as the stroke size in untreated rats (200 ± 103 mm3) was even larger than that in the Ad.RSVlacZ treated control rats (Fig. 2B) .
The mechanism by which IL-1ra reduces isch emic brain damage is unknown, although it is likely to involve blockade of some as p ect of IL-1 action in brain, such as arachidonic acid release, nitric oxide p roduction, or stimulation of inflammatory reac tions (Rothwell and Relton, 1993) . As a p otential therapeutic modality directed at inhibition of neu ro p e p tide action, the use of secreted p e p tide rece p tor antagonists is a pp ealing because the drugs act at extracellular sites, which may be more accessible than intracellular sites. In the brain, access to the extracellular s p ace of even large molecules such as p e p tides can be gained through the CSF (Rennels et aI., 1985) . Furthermore, as a scheme for gene ther a p y, the ex p ression of transgenes that p roduce p e p tides that act at extracellular sites is advantageous because it is not necessary to alter gene ex p ression directly in the cells that are injured by the disease p rocess. As shown here, the synthesis and secre tion of a transgene-derived p rotein by the cells that line the cerebral ventricles can have a marked effect on the injury that occurs in distant cells not ex p ress ing the transgene. Finally, whereas transient gene ex p ression could be a limitation for gene thera p y of metabolic diseases, the 3-5-week p eriod of gene ex p ression that accom p anies the use of adenoviral vectors (Davidson et aI., 1993) may be an advan tage in diseases like ischemia in which normal re p air p rocesses such as angiogenesis can eventu ally obviate the need for continuing thera p eutic intervention.
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